Beijing, China

Xiaocong Yu


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 41(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):

Title: Innovations of Xiaocong Yu in Cancer Treatment

Introduction

Xiaocong Yu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer treatment, particularly in the development of bispecific antibodies. His innovative work aims to provide new therapeutic options for patients suffering from ovarian cancer.

Latest Patents

Xiaocong Yu holds a patent for an "Anti human ovarian cancer-anti CD3 bispecific antibody." This invention provides a bispecific antibody designed to target ovarian cancer. The antibody consists of two polypeptide domains connected by a polypeptide linker. One domain is an anti-ovarian cancer antibody, or its Fab fragment, single complementarity determining region (CDR) antibody, or single chain Fv (scFv). The other domain is an anti-CD3 antibody, or its Fab fragment, single CDR antibody, or scFv. Additionally, the invention includes DNA sequences encoding the antibody, an expression vector containing the DNA sequence, and a host cell containing the expression vector. Xiaocong Yu's innovative approach has the potential to enhance the effectiveness of cancer therapies.

Career Highlights

Xiaocong Yu is associated with Beijing Abt Genetic Engineering Technology Co. Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to improving cancer treatment methodologies through innovative biotechnological solutions.

Collaborations

Xiaocong Yu collaborates with notable colleagues in his field, including Hualiang Huang and Xin Jiang. Their combined expertise contributes to the advancement of cancer research and the development of new therapeutic strategies.

Conclusion

Xiaocong Yu's contributions to the field of cancer treatment through his innovative bispecific antibody patent demonstrate his commitment to improving patient outcomes. His work at Beijing Abt Genetic Engineering Technology Co. Ltd. and collaborations with esteemed colleagues further highlight the importance of innovation in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…